Document:

Amendment to Expense Support Agreement

 Exhibit 10.1 

 

			
	

	  	 450 S. Orange Avenue
 Orlando, FL 32801
 Tel 866.745.3797

Fax 407.540.7653
 www.CorporateCapitalTrust.com
  
 Mailing Address:
 P.O. Box 4920

Orlando, Florida 32802-4920

 December 16, 2011 
  

			
	 CNL Fund Advisors Company
 450 S. Orange Avenue
 Orlando, FL 32801
 Attention: Paul S. Saint-Pierre
 Chief Financial Officer
	  	 KKR Asset Management LLC

555 California Street, 50th Floor
 San Francisco,
CA 94104
 Attention: Nicole J. Macarchuk

General Counsel

  

	 	RE:	Amendment 2 to Expense Support and Conditional Reimbursement Agreement Dated as of June 7, 2011, as amended 

Ladies and Gentlemen: 
 This
letter confirms our intent that, effective as of immediately before the close of business on December 31, 2011, in accordance with Section 4.4 thereof, the above-referenced agreement among us (the “Agreement”) is hereby amended
as follows: 
  

	 	1.	The reference to “December 31, 2011” in Section 1 of the Agreement is hereby deleted, and “March 31, 2012” is inserted in the place of such
deleted reference. 

  

	 	2.	Each reference to “50%” in Section 1 of the Agreement is hereby deleted, and “32.5%” is inserted in the place of each such deleted reference.

  

	 	3.	The definition of “(b) “Operating Expenses”“ in Section 1 of the Agreement is hereby deleted in its entirety and the following definition is
inserted in the place of such deleted definition: “(b) “Operating Expenses” for any period means all costs and expenses paid or incurred by the Company, as determined under generally accepted accounting principles, including base
advisory fees payable pursuant to the Advisory Agreements, and excluding (i) incentive advisory fees payable pursuant to the Advisory Agreements, (ii) offering and organization expenses, and (iii) all interest costs related to
indebtedness for such period, if any.” 

  

	 	4.	All references in the Agreement to “Agreement” shall be deemed to mean the Agreement as modified by this letter. This letter shall be deemed incorporated into
and to form part of the Agreement. Except as modified hereby, the Agreement remains in full force and effect in accordance with its terms. 

 If the foregoing accurately reflects our agreement, please indicate your acceptance hereof by countersigning a copy of this letter and returning a counterpart of such copy to the attention of the
undersigned. Thank you. 
  
  

Corporate Capital Trust, Inc. is advised by CNL Fund Advisors Company and KKR Asset Management, LLC 

 
	
	Sincerely,
	
	/s/ Andrew A. Hyltin
	 Andrew A. Hyltin
 President
and Chief Executive Officer

  

									
	 AGREED AND ACCEPTED:
  

CNL FUND ADVISORS COMPANY
	 		 	 AGREED AND ACCEPTED:
  

KKR ASSET MANAGEMENT LLC

					
	By:	 	/s/ Paul S. Saint-Pierre	 		 	By:	 	/s/ Nicole J. Macarchuk
	Name:	 	Paul S. Saint-Pierre	 		 	Name:	 	Nicole J. Macarchuk
	Title:	 	Chief Financial Officer	 		 	Title:	 	General Counsel

  
 2Royalty Termination Agreement

 Exhibit 10.57 
 ROYALTY TERMINATION AGREEMENT 
 THIS ROYALTY TERMINATION
AGREEMENT (this “Agreement”) is made as of November 17, 2010, by and between BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Biovest”), and ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation
(“Accentia”). 
 RECITALS 
 WHEREAS, pursuant to that certain Royalty Agreement dated as of October 31, 2006, as amended by a letter agreement dated February 5, 2008 (the “Royalty Agreement”), by
and between Biovest and Accentia, Biovest granted to Accentia a royalty equal to nineteen and one-half percent (19.5%) of net sales and licensing revenue received by Biovest from any Biovest Biologic Products (the “Royalty”);

 WHEREAS, pursuant to that certain Term Loan and Security Agreement (the “Security Agreement”) dated
as of November 17, 2010, by and among Biovest, the Lenders party thereto and Agent, the parties hereto, in consideration for the acceptance by certain of the Prepetition Lenders of the allowed secured claims against Biovest as provided therein
and other consideration, have agreed, among other things, to the termination of the Royalty Agreement and the Royalty; and 

WHEREAS, pursuant to the terms and conditions of the Security Agreement and the Confirmed Plan, Biovest and Accentia hereby desire
to terminate the Royalty Agreement and the Royalty effective as of the date of this Agreement. 
 NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Security Agreement. 
 2. The parties hereto agree that the above Recitals are true and correct in all respects. 
 3. The parties hereto hereby consent to the termination of the Royalty Agreement and the Royalty (and all of the rights and obligations created thereunder) effective as of the date of this Agreement.

 4. Accentia hereby acknowledges and agrees that it shall have no claims of any nature whatsoever against Biovest as a result
of the termination of the Royalty Agreement and the Royalty. 
 5. This Agreement shall be binding upon the parties hereto and
their respective successors and assigns. The parties hereto agree that this Agreement is fully and adequately supported by consideration, is fair and reasonable, and that they have had the opportunity to discuss this matter with counsel of their
choice. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one agreement. It is understood and agreed that if facsimile copies of this
Agreement bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding, and enforceable as if such signed facsimile copies
were original documents bearing original signature. 

  
 -1-

 6. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND ENFORCED ACCORDING
TO, THE LAWS OF THE STATE OF FLORIDA, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE COURTS OF FLORIDA OR IN THE
FEDERAL COURTS LOCATED IN THE STATE OF FLORIDA. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. Wherever possible each provision of this Agreement shall be interpreted in such
manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 [remainder of page intentionally
left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Royalty Termination Agreement
as of the date first above written. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ David Moser

	Name:	 	David Moser
	Title:	 	Secretary
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Samuel S. Duffey

	Name:	 	Samuel S. Duffey
	Title:	 	President
	
	ACCEPTED AND AGREED:
	
	LV ADMINISTRATIVE SERVICES, INC.
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	LAURUS MASTER FUND, LTD. (IN LIQUIDATION)
		
	By:	 	 /s/ Russell Smith

	Name: Russell Smith
	Title: Joint Official Liquidator (with no personal liability)
	
	VALENS U.S. SPV I, LLC
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	VALENS OFFSHORE SPV I, LTD.
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	VALENS OFFSHORE SPV II, CORP.
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory

 
			
	PSOURCE STRUCTURED DEBT LIMITED
	By: PSource Capital Ltd., It’s Investment Consultant
		
	By:	 	 /s/ Charles Lews

	Name: Charles Lews
	Title: Authorized SignatoryClass 4 Plan Promissory Note

 Exhibit 10.58 
 THIS NOTE IS EXECUTED AND DELIVERED AS PART OF THE CONFIRMED FIRST AMENDED JOINT PLAN OF REORGANIZATION OF ACCENTIA BIOPHARMACEUTICALS, INC., ANALYTICA INTERNATIONAL, INC., TEAMM PHARMACEUTICALS, INC.,
ACCENTRX, INC., AND ACCENTIA SPECIALTY PHARMACY, INC., AS MODIFIED, IN THE JOINTLY ADMINISTERED CHAPTER 11 CASE STYLED IN RE: ACCENTIA BIOPHARMACEUTICALS, INC., CASE NO. 8:08-BK-17795-KRM, IN THE UNITED STATES BANKRUPTCY COURT FOR THE MIDDLE
DISTRICT OF FLORIDA, TAMPA DIVISION, AND IS, THEREFORE, EXEMPT FROM DOCUMENTARY STAMP TAX PURSUANT TO 11 U.S.C. §1146(a). 
 CLASS 4 PLAN PROMISSORY NOTE 
  

			
	U.S. $4,342,770.50	  	 Tampa, Florida
 November 17, 2010

 FOR VALUE RECEIVED, the undersigned, ACCENTIA BIOPHARMACEUTICALS, INC., a Florida
corporation (“Maker”), with a mailing address of 324 South Hyde Park Avenue, Suite 350, Tampa, Florida 33606, promises to pay to the order of MCKESSON CORPORATION, a Delaware corporation (“McKesson”), at One Post
Street, 20th Floor, San Francisco, California 94104-5296,
or at such other place or places as McKesson may from time to time designate, the principal sum of Four Million Three Hundred Forty-Two Thousand Seven Hundred Seventy and 50/100 Dollars ($4,342,770.50) (the “Principal Amount”),
together with interest on the unpaid Principal Amount outstanding in the manner and at the time hereinafter provided. 
 On
November 10, 2008, Maker and its subsidiaries filed their Voluntary Petitions for relief under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court for the Middle District of Florida, Tampa Division (the “Bankruptcy
Court”), which cases have been jointly administered under Case No. 8:08-bk-17795-KRM (the “Bankruptcy Cases”). Maker has filed a First Amended Joint Plan of Reorganization dated as of August 16, 2010 (as modified,
the “Plan”) in the Bankruptcy Cases. On November 2, 2010, the Bankruptcy Court entered an order confirming the Plan (the “Confirmation Order”), and the Plan became effective on November 17, 2010. This
Class 4 Plan Promissory Note (hereinafter, the “Note”) is being executed and delivered by Maker pursuant to the terms of the Plan and the Confirmation Order. 
 Maker further promises to pay interest on the unpaid Principal Amount outstanding hereunder from the date hereof until the “Maturity Date” (as defined below) at a rate equal at all times to five
percent (5%) per annum, based on a year of 365 days for actual days elapsed (the “Contract Rate”). From and after the Maturity Date and until payment in full of all sums owing hereunder, interest shall accrue and be payable on
the outstanding Principal Amount owing under this Note at a rate equal to the Contract Rate plus five percent (5%) per annum, based on a year of 365 days for actual days elapsed. 

 1. Payments. 

(a) Payments. Maker shall repay to McKesson the Principal Amount and all interest owing hereunder by no later than
the date (the “Maturity Date”) that is the first to occur of: 
  

	 	(i)	March 17, 2014, and/or 

  

	 	(ii)	The date upon which one of the Events of Default under Section 3 of this Note occurs. 

(b) Prepayment. Maker may prepay the obligations owing hereunder at any time without premium or penalty.

 2. Representations and Warranties. 

(a) Organization and Powers. Maker, as of the execution of this Note and continuing until payment in full hereof,
(i) is and shall be duly organized, validly existing, and in good standing under the laws of the State of Florida, (ii) has and shall have all requisite power and authority to own its assets and carry on its business and to execute,
deliver and perform its obligations hereunder and under the Plan, (iii) is and shall be qualified to do business and is and shall be in good standing in each jurisdiction in which the failure to so qualify or be in good standing would result in
a Material Adverse Change (as defined below), and (iv) is and shall be in compliance with all applicable laws, except to the extent that such noncompliance could not reasonably be expected to result in a Material Adverse Change. For purposes of
this Note, “Material Adverse Change” means (y) a material adverse change in the business, operations or financial condition of Maker and/or Biovest International, Inc. (“Biovest”) or (z) any event, matter,
condition or circumstance which (A) would materially impair the ability of Maker to perform or observe its obligations under or in respect of this Note or in respect of the Plan, or (B) affects the legality, validity, binding effect or
enforceability of this Note or the Plan. For purposes of this Note, Material Adverse Change shall not mean a sale of substantially all of the assets of Analytica International, Inc. 

(b) Authorization; No Conflict. The execution, delivery and performance by Maker of this Note have been duly
authorized by all necessary action of Maker and do not and will not (i) contravene the terms of the articles of incorporation, or bylaws, of Maker or result in a breach of or constitute a default under any material contract, instrument, plan of
reorganization or other agreement to which Maker is a party or by which it or its properties may be bound or affected; or (ii) violate any provision of any law, rule, regulation, order, judgment, decree or the like binding on or affecting
Maker. 
 (c) Binding Obligations. This Note constitutes, or when delivered to McKesson will constitute, a
legal, valid and binding obligation of Maker, enforceable against Maker in accordance with its express written terms, except as limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting
creditors’ rights generally and by general equity principles. 

  
 2 

 (d) Consents. No authorization, approval, consent, license, exemption
of, or filing or registration with, any person or entity is required for the due execution, delivery or performance by Maker of this Note. 
 3. Events of Default. The occurrence of any of the following events shall constitute an event of default (“Event of Default”) under this Note: 

 

	 	(i)	Any of the representations and warranties of Maker set forth above in this Note shall fail to have been true when made or shall become untrue at any time prior to
payment in full of this Note; 

  

	 	(ii)	The Plan as in effect on the date hereof shall be modified without McKesson’s prior written consent, or a motion shall be filed seeking approval of a modification
of the Plan to which McKesson has not consented before such motion is filed; 

  

	 	(iii)	A material default or breach shall occur under the Plan that is not cured within thirty (30) days of the occurrence thereof (or such other date as permitted by
order of the Bankruptcy Court), it being agreed that each and all payment obligations under the Plan and the timeliness thereof are material; 

  

	 	(iv)	Maker or Biovest shall hereafter become a debtor in a case under title 11 of the United States Code, or shall make a general assignment for the benefit of creditors, or
shall transfer substantially all of its assets without the prior written consent of McKesson, or shall dissolve, or shall suffer a change in control to occur including by virtue of the appointment of a trustee or custodian; 

 

	 	(v)	Any creditor of Maker or Biovest shall begin to exercise its creditors’ rights and remedies with respect to Maker or Biovest or their respective assets, which
exercise would result in a Material Adverse Change as to Maker or Biovest; and 

  

	 	(vi)	A default or event of default shall occur under any security agreement or pledge agreement executed by any person or entity to secure the payment or performance of this
Note, including the Pledge Agreement (as defined below). 

 4. Additional Agreements of Maker. Maker
promises to pay on the Maturity Date (and thereafter on demand) all costs and expenses, including reasonable attorneys’ fees, incurred by McKesson (including allocated costs and expenses for internal legal services) in connection with
(i) the enforcement or attempted enforcement of, and preservation of any rights or interests of McKesson under, this Note, the Plan (including any litigation concerning modifications thereof), and any other documents executed in connection with
this Note or the Plan or pursuant thereto, and/or (ii) the negotiation and documentation of any modifications or supplements to this Note or the Plan and the cost of due diligence reasonably conducted in connection therewith. Maker and any
endorsers of this Note, for the maximum period of time and the full extent permitted by law, (a) waive diligence, presentment, demand, notice of nonpayment, protest, notice of protest, and notice of every kind; (b) waive the right to
assert the defense of any statute of limitations to any debt or obligation hereunder; and (c) consent to renewals and extensions of time for the payment of any amounts due under this Note. In any action brought under or arising out of this
Note, Maker, including its successors and assigns, hereby consent to the jurisdiction of any competent court within the State of California, County of San Francisco, and Maker further consents to service of process by any means authorized by
California law. This Note shall be construed in accordance with and governed by the laws of the State of California. 

  
 3 

 5. Indemnification of McKesson. Maker hereby agrees to indemnify McKesson, its
officers, directors, employees and affiliates (each, an “Indemnified Person”), against, and hold each of them harmless from, any and all liabilities, obligations, losses, claims, damages, penalties, actions, judgments, suits, costs,
expenses or disbursements of any kind or nature whatsoever, including the reasonable fees and disbursements of counsel to an Indemnified Person (including allocated costs of internal counsel), which may be imposed on, incurred by, or asserted
against any Indemnified Person, (i) in any way relating to or arising out of this Note, the collateral therefor, and/or transactions relating to the foregoing or any of the transactions contemplated hereby or thereby, including in connection
with any future bankruptcy of Maker or any guarantor or (ii) with respect to any investigation, litigation or other proceeding relating to any of the foregoing and/or relating to Maker, irrespective of whether the Indemnified Person shall be
designated a party thereto (collectively, the “Indemnified Liabilities”); provided that Maker shall not be liable to any Indemnified Person for any portion of such Indemnified Liabilities to the extent they are found by a final
decision of a court of competent jurisdiction to have resulted from such Indemnified Person’s gross negligence or willful misconduct. If and to the extent that the foregoing indemnification is for any reason held unenforceable, Maker agrees to
make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. 
 6. Pledge Agreement. This Note is secured by that certain Stock Pledge Agreement of even date herewith by and between Maker and McKesson (the “Pledge Agreement”), granting to
McKesson a first priority security interest in 6,103,818 shares of the common stock, par value $.01 per share, of Biovest owned by Maker, as more particularly described in the Pledge Agreement. 

IN WITNESS WHEREOF, Maker, by its duly authorized legal representative, has executed this Note as of the date and year first above
mentioned. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.,
	a Florida corporation
		
	By:	 	 /s/ Samuel S. Duffey

	Name:	 	Samuel S. Duffey
	Title:	 	President

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]